Photo of Anthony L. Zietman, MD FASTRO

Anthony L. Zietman, MD FASTRO

Massachusetts General Hospital

Massachusetts General Hospital
Phone: (617) 726-5866
Fax: (617) 726-3603


azietman@partners.org

Photo of Anthony L. Zietman, MD FASTRO

Massachusetts General Hospital
Phone: (617) 726-5866
Fax: (617) 726-3603


azietman@partners.org

Visualize Collaborations
Learn how these members are similar
Similar Members

DF/HCC members that share similar concepts* with Anthony L. Zietman, MD FASTRO but have yet to coauthor a publication with this researcher.

* Concepts are MeSH terms, automatically derived from member publications

Similar Members

Anthony L. Zietman, MD FASTRO

Massachusetts General Hospital

EDUCATIONAL TITLES

  • Jenot W. and William U. Shipley Professor of Radiation Oncology, Radiation Oncology, Harvard Medical School
  • Associate Director, Radiation Oncology Residency Program, Massachusetts General Hospital

DF/HCC PROGRAM AFFILIATION

Research Abstract

Research interests include:

-active surveillance in prostate cancer

-the potential role of protonbeam therapy in prostate cancer

-the role of chemo-radiation in bladder cancer

-ethics of scientific publishing

Publications from Harvard Catalyst Profiles

Powered by Harvard Catalyst
  • Kamran SC, Zietman AL. Radiation treatment in prostate cancer: covering the waterfront. BJU Int 2021. PubMed
  • Kamran SC, Palma D, Katz MS, Zietman AL. Technical Giants But Biologic Infants: Defining a More Sophisticated Role for Local Therapy in Metastatic Disease. Semin Radiat Oncol 2021; 31:200-204. PubMed
  • Franco I, Oladeru OT, Saraf A, Liu KX, Milligan M, Zietman A, Nguyen PL, Hirsch AE, Jimenez R. Improving Diversity and Inclusion in the Post-COVID Era through a Radiation Oncology Intensive Shadowing Experience (RISE). Adv Radiat Oncol 2020. PubMed
  • Lowrance WT, Breau RH, Chou R, Chapin BF, Crispino T, Dreicer R, Jarrard DF, Kibel AS, Morgan TM, Morgans AK, Oh WK, Resnick MJ, Zietman AL, Cookson MS. Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART II. J Urol 2020. PubMed
  • Lowrance WT, Breau RH, Chou R, Chapin BF, Crispino T, Dreicer R, Jarrard DF, Kibel AS, Morgan TM, Morgans AK, Oh WK, Resnick MJ, Zietman AL, Cookson MS. Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART I. J Urol 2020. PubMed
  • Kamran SC, Zietman AL. Curing Metastatic Disease With Ablative Radiation Therapy: Separating Truth From Wish. Int J Radiat Oncol Biol Phys 2020; 107:433-436. PubMed
  • Dess RT, Sun Y, Jackson WC, Jairath NK, Kishan AU, Wallington DG, Mahal BA, Stish BJ, Zumsteg ZS, Den RB, Hall WA, Gharzai LA, Jaworski EM, Reichert ZR, Morgan TM, Mehra R, Schaeffer EM, Sartor O, Nguyen PL, Lee WR, Rosenthal SA, Michalski JM, Schipper MJ, Dignam JJ, Pisansky TM, Zietman AL, Sandler HM, Efstathiou JA, Feng FY, Shipley WU, Spratt DE. Association of Presalvage Radiotherapy PSA Levels After Prostatectomy With Outcomes of Long-term Antiandrogen Therapy in Men With Prostate Cancer. JAMA Oncol 2020. PubMed
  • Elmore SNC, Royce TJ, Oladeru OT, Freese CM, Wakefield DV, Vapiwala N, Zietman AL. Global Health Perspectives among Radiation Oncology Residency Program Directors: A Knowledge, Attitudes, and Practices Survey. Int J Radiat Oncol Biol Phys 2020. PubMed
  • Vapiwala N, Thomas CR, Grover S, Yap ML, Mitin T, Shulman LN, Gospodarowicz MK, Longo J, Petereit DG, Ennis RD, Hayman JA, Rodin D, Buchsbaum JC, Vikram B, Abdel-Wahab M, Epstein AH, Okunieff P, Goldwein J, Kupelian P, Weidhaas JB, Tucker MA, Boice JD, Fuller CD, Thompson RF, Trister AD, Formenti SC, Barcellos-Hoff MH, Jones J, Dharmarajan KV, Zietman AL, Coleman CN. Enhancing Career Paths for Tomorrow's Radiation Oncologists. Int J Radiat Oncol Biol Phys 2019. PubMed
  • Salari K, Kuppermann D, Preston MA, Dahl DM, Barrisford GW, Efstathiou JA, Blute ML, Vesprini D, Loblaw A, Zietman AL, Klotz L, Feldman AS. Active Surveillance of Prostate Cancer is a Viable Option for Men Younger than 60 Years. J Urol 2019; 201:721-727. PubMed
  • Zietman AL. Can proton therapy be considered a standard of care in oncology? Lessons from the United States. Br J Cancer 2019. PubMed
  • Soni PD, Hartman HE, Dess RT, Abugharib A, Allen SG, Feng FY, Zietman AL, Jagsi R, Schipper MJ, Spratt DE. Comparison of Population-Based Observational Studies With Randomized Trials in Oncology. J Clin Oncol 2019. PubMed
  • Coen JJ, Zhang P, Saylor PJ, Lee CT, Wu CL, Parker W, Lautenschlaeger T, Zietman AL, Efstathiou JA, Jani AB, Kucuk O, Souhami L, Rodgers JP, Sandler HM, Shipley WU. Bladder Preservation With Twice-a-Day Radiation Plus Fluorouracil/Cisplatin or Once Daily Radiation Plus Gemcitabine for Muscle-Invasive Bladder Cancer: NRG/RTOG 0712-A Randomized Phase II Trial. J Clin Oncol 2019; 37:44-51. PubMed
  • Moteabbed M, Trofimov A, Khan FH, Wang Y, Sharp GC, Zietman AL, Efstathiou JA, Lu HM. Impact of interfractional motion on hypofractionated pencil beam scanning proton therapy and VMAT delivery for prostate cancer. Med Phys 2018. PubMed
  • Aragon-Ching JB, Werntz RP, Zietman AL, Steinberg GD. Multidisciplinary Management of Muscle-Invasive Bladder Cancer: Current Challenges and Future Directions. Am Soc Clin Oncol Educ Book 2018. PubMed
  • Hwang WL, Tendulkar RD, Niemierko A, Agrawal S, Stephans KL, Spratt DE, Hearn JW, Koontz BF, Lee WR, Michalski JM, Pisansky TM, Liauw SL, Abramowitz MC, Pollack A, Moghanaki D, Anscher MS, Den RB, Zietman AL, Stephenson AJ, Efstathiou JA. Comparison Between Adjuvant and Early-Salvage Postprostatectomy Radiotherapy for Prostate Cancer With Adverse Pathological Features. JAMA Oncol 2018. PubMed
  • Wo JY, Drapek LC, Niemierko A, Silvia B, Noé BN, Russo AL, Miyamoto DT, Hong TS, Efstathiou JA, Zietman AL, Dizon DS. Clinical needs assessment for sexual health among cancer patients receiving pelvic radiation: Implications for development of a radiation oncology sexual health clinic. 2017. PubMed
  • Ramey SJ, Agrawal S, Abramowitz MC, Moghanaki D, Pisansky TM, Efstathiou JA, Michalski JM, Spratt DE, Hearn JWD, Koontz BF, Liauw SL, Pollack A, Anscher MS, Den RB, Stephans KL, Zietman AL, Lee WR, Stephenson AJ, Tendulkar RD. Multi-institutional Evaluation of Elective Nodal Irradiation and/or Androgen Deprivation Therapy with Postprostatectomy Salvage Radiotherapy for Prostate Cancer. Eur Urol 2017. PubMed
  • Chang SS, Bochner BH, Chou R, Dreicer R, Kamat AM, Lerner SP, Lotan Y, Meeks JJ, Michalski JM, Morgan TM, Quale DZ, Rosenberg JE, Zietman AL, Holzbeierlein JM. Treatment of Nonmetastatic Muscle-Invasive Bladder Cancer: American Urological Association/American Society of Clinical Oncology/American Society for Radiation Oncology/Society of Urologic Oncology Clinical Practice Guideline Summary. J Oncol Pract 2017; 13:621-625. PubMed
  • Sanchez A, Wszolek MF, Niemierko A, Clayman RH, Drumm M, Rodríguez D, Feldman AS, Dahl DM, Heney NM, Shipley WU, Zietman AL, Efstathiou JA. Incidence, clinicopathologic risk factors, management and outcomes of non-muscle invasive recurrences after complete response to tri-modality therapy for muscle-invasive bladder cancer. J Urol 2017. PubMed
  • Rodin D, Drumm M, Clayman R, Buscariollo DL, Galland-Girodet S, Eidelman A, Feldman AS, Dahl DM, McGovern FJ, Olumi AF, Niemierko A, Shipley WU, Zietman AL, Efstathiou JA. Risk Factors for Disease Progression After Postprostatectomy Salvage Radiation: Long-term Results of a Single-institution Experience. Clin Genitourin Cancer 2017. PubMed
  • Zietman AL. Frailty is our Destiny: An Introduction to the Red Journal's Special Edition on Radiation Therapy in the Elderly. Int J Radiat Oncol Biol Phys 2017; 98:713-714. PubMed
  • Jang JW, Drumm MR, Efstathiou JA, Paly JJ, Niemierko A, Ancukiewicz M, Talcott JA, Clark JA, Zietman AL. Long-term quality of life after definitive treatment for prostate cancer: patient-reported outcomes in the second posttreatment decade. Cancer Med 2017. PubMed
  • Xiang HF, Lu HM, Efstathiou JA, Zietman AL, Armas R, Harris K, Bloch BN, Qureshi MM, Keohan S, Hirsch AE. Dosimetric impacts of endorectal balloon in CyberKnife stereotactic body radiation therapy (SBRT) for early-stage prostate cancer. J Appl Clin Med Phys 2017; 18:37-43. PubMed
  • Chang SS, Bochner BH, Chou R, Dreicer R, Kamat AM, Lerner SP, Lotan Y, Meeks JJ, Michalski JM, Morgan TM, Quale DZ, Rosenberg JE, Zietman AL, Holzbeierlein JM. Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline. J Urol 2017. PubMed
  • Smith GL, Ganz PA, Bekelman JE, Chmura SJ, Dignam JJ, Efstathiou JA, Jagsi R, Johnstone PA, Steinberg ML, Williams SB, Yu JB, Zietman AL, Weichselbaum RR, Tina Shih YC. Promoting the Appropriate Use of Advanced Radiation Technologies in Oncology: Summary of a National Cancer Policy Forum Workshop. Int J Radiat Oncol Biol Phys 2017; 97:450-461. PubMed
  • Underwood TS, Voog JC, Moteabbed M, Tang S, Soffen E, Cahlon O, Lu HM, Zietman AL, Efstathiou JA, Paganetti H. Hydrogel rectum-prostate spacers mitigate the uncertainties in proton relative biological effectiveness associated with anterior-oblique beams. Acta Oncol 2017. PubMed
  • Giacalone NJ, Shipley WU, Clayman RH, Niemierko A, Drumm M, Heney NM, Michaelson MD, Lee RJ, Saylor PJ, Wszolek MF, Feldman AS, Dahl DM, Zietman AL, Efstathiou JA. Long-term Outcomes After Bladder-preserving Tri-modality Therapy for Patients with Muscle-invasive Bladder Cancer: An Updated Analysis of the Massachusetts General Hospital Experience. Eur Urol 2017. PubMed
  • Shipley WU, Seiferheld W, Lukka HR, Major PP, Heney NM, Grignon DJ, Sartor O, Patel MP, Bahary JP, Zietman AL, Pisansky TM, Zeitzer KL, Lawton CA, Feng FY, Lovett RD, Balogh AG, Souhami L, Rosenthal SA, Kerlin KJ, Dignam JJ, Pugh SL, Sandler HM, . Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer. N Engl J Med 2017; 376:417-428. PubMed
  • Krasnow RE, Drumm M, Roberts HJ, Niemierko A, Wu CL, Wu S, Zhang J, Heney NM, Wszolek MF, Blute ML, Feldman AS, Lee RJ, Zietman AL, Shipley WU, Efstathiou JA. Clinical Outcomes of Patients with Histologic Variants of Urothelial Cancer Treated with Trimodality Bladder-sparing Therapy. Eur Urol 2016. PubMed
  • Mak KS, Smith AB, Eidelman A, Clayman R, Niemierko A, Cheng JS, Matthews J, Drumm MR, Nielsen ME, Feldman AS, Lee RJ, Zietman AL, Chen RC, Shipley WU, Milowsky MI, Efstathiou JA. Quality of Life in Long-term Survivors of Muscle-Invasive Bladder Cancer. Int J Radiat Oncol Biol Phys 2016; 96:1028-1036. PubMed
  • Pisansky TM, Agrawal S, Hamstra DA, Koontz BF, Liauw SL, Efstathiou JA, Michalski JM, Feng FY, Abramowitz MC, Pollack A, Anscher MS, Moghanaki D, Den RB, Stephans KL, Zietman AL, Lee WR, Kattan MW, Stephenson AJ, Tendulkar RD. Salvage Radiation Therapy Dose Response for Biochemical Failure of Prostate Cancer After Prostatectomy-A Multi-Institutional Observational Study. Int J Radiat Oncol Biol Phys 2016; 96:1046-1053. PubMed
  • Roberts HJ, Zietman AL, Efstathiou JA. Painting Dose: The ART of Radiation. Int J Radiat Oncol Biol Phys 2016; 96:722-728. PubMed
  • Tendulkar RD, Agrawal S, Gao T, Efstathiou JA, Pisansky TM, Michalski JM, Koontz BF, Hamstra DA, Feng FY, Liauw SL, Abramowitz MC, Pollack A, Anscher MS, Moghanaki D, Den RB, Stephans KL, Zietman AL, Lee WR, Kattan MW, Stephenson AJ. Contemporary Update of a Multi-Institutional Predictive Nomogram for Salvage Radiotherapy After Radical Prostatectomy. J Clin Oncol 2016. PubMed
  • Lee JY, Daignault-Newton S, Heath G, Scarlett S, Sanda MG, Chang P, Regan MM, Michalski JM, Sandler HM, Feng FY, Kuban DA, Zietman AL, Ciezki JP, Kaplan ID, Crociani C, McLaughlin WP, Mantz CA, Finkelstein SE, Suy S, Collins SP, Garin O, Ferrer M, Hamstra DA, Spratt DE. Multinational Prospective Study of Patient-Reported Outcomes After Prostate Radiation Therapy: Detailed Assessment of Rectal Bleeding. Int J Radiat Oncol Biol Phys 2016. PubMed
  • Zietman AL, Smith J, Klein E, Droller M, Dasgupta P, Catto J. Editorial Statement on Gleason Scoring for Prostate Cancer. Int J Radiat Oncol Biol Phys 2016; 95:1092. PubMed
  • Wallner PE, Gerdeman A, Willis JM, Zietman AL. The American Board of Radiology radiation oncology Maintenance of Certification Part 3 Modular Examination: Evaluation of the first administration. 2016. PubMed
  • Moteabbed M, Trofimov A, Sharp GC, Wang Y, Zietman AL, Efstathiou JA, Lu HM. A Prospective Comparison of the Effects of Interfractional Variations on Proton Therapy and Intensity Modulated Radiation Therapy for Prostate Cancer. Int J Radiat Oncol Biol Phys 2016; 95:444-53. PubMed
  • Zietman AL. Making Radiation Therapy for Prostate Cancer More Economical and More Convenient. J Clin Oncol 2016. PubMed
  • Lam KO, Lee AW, Choi CW, Sze HC, Zietman AL, Hopkins KI, Rosenblatt E. Global Pattern of Nasopharyngeal Cancer: Correlation of Outcome With Access to Radiation Therapy. Int J Radiat Oncol Biol Phys 2016; 94:1106-12. PubMed
  • Mitin T, George A, Zietman AL, Heney NM, Kaufman DS, Uzzo RG, Dreicer R, Wallace HJ, Souhami L, Dobelbower MC, Sandler HM, Shipley WU. Long-Term Outcomes Among Patients Who Achieve Complete or Near-Complete Responses After the Induction Phase of Bladder-Preserving Combined-Modality Therapy for Muscle-Invasive Bladder Cancer: A Pooled Analysis of NRG Oncology/RTOG 9906 and 0233. Int J Radiat Oncol Biol Phys 2016; 94:67-74. PubMed
  • Eyler CE, Zietman AL. A (relatively) risky business: the link between prostatic radiotherapy and second malignancies. BMJ 2016; 352:i1073. PubMed
  • Gray PJ, Zietman AL. Dose-Escalated Radiotherapy for Prostate Cancer: Is the Sky the Limit? JAMA Oncol 2015; 1:883-4. PubMed
  • Evans JR, Zhao S, Daignault S, Sanda MG, Michalski J, Sandler HM, Kuban DA, Ciezki J, Kaplan ID, Zietman AL, Hembroff L, Feng FY, Suy S, Skolarus TA, McLaughlin PW, Wei JT, Dunn RL, Finkelstein SE, Mantz CA, Collins SP, Hamstra DA, . Patient-reported quality of life after stereotactic body radiotherapy (SBRT), intensity modulated radiotherapy (IMRT), and brachytherapy. Radiother Oncol 2015; 116:179-84. PubMed
  • Wallner PE, Steinberg ML, McBride WH, Hahn SM, Zietman AL. A fork in the road: choosing the path of relevance. Int J Radiat Oncol Biol Phys 2015; 92:214-6. PubMed
  • Gray PJ, Zietman AL. Androgen deprivation with radiotherapy: how long is long enough? Lancet Oncol. 2015; 16:244-6. PubMed
  • Delahunt B, Hammond E, Egevad L, Samaratunga H, Srigley JR, Humphrey PA, Rubin M, Epstein JI, Lin DW, Gore JL, Nacey JN, Klotz L, Sandler H, Zietman AL, Holden S, Montironi R, Evans AJ, McKenney JK, Berney D, Wheeler TM, Chinnaiyan AM, True L, Knudsen B, Amin MB. Active surveillance for prostate cancer: the role of the pathologist. Pathology 2015; 47:1-3. PubMed
  • Montironi R, Hammond EH, Lin DW, Gore JL, Srigley JR, Samaratunga H, Egevad L, Rubin MA, Nacey J, Klotz L, Sandler H, Zietman AL, Holden S, Humphrey PA, Evans AJ, Delahunt B, McKenney JK, Berney D, Wheeler TM, Chinnaiyan A, True L, Knudsen B, Epstein JI, Amin MB, , , . Consensus statement with recommendations on active surveillance inclusion criteria and definition of progression in men with localized prostate cancer: the critical role of the pathologist. Virchows Arch 2014. PubMed
  • Mak RH, Hunt D, Shipley WU, Efstathiou JA, Tester WJ, Hagan MP, Kaufman DS, Heney NM, Zietman AL. Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combined-modality therapy: a pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233. J Clin Oncol 2014; 32:3801-9. PubMed
  • Amin MB, Lin DW, Gore JL, Srigley JR, Samaratunga H, Egevad L, Rubin M, Nacey J, Carter HB, Klotz L, Sandler H, Zietman AL, Holden S, Montironi R, Humphrey PA, Evans AJ, Epstein JI, Delahunt B, McKenney JK, Berney D, Wheeler TM, Chinnaiyan AM, True L, Knudsen B, Hammond ME. The critical role of the pathologist in determining eligibility for active surveillance as a management option in patients with prostate cancer: consensus statement with recommendations supported by the College of American Pathologists, International Soci Arch Pathol Lab Med 2014; 138:1387-405. PubMed
  • Talcott JA, Manola J, Chen RC, Clark JA, Kaplan I, D'Amico AV, Zietman AL. Using patient-reported outcomes to assess and improve prostate cancer brachytherapy. BJU Int 2014. PubMed
  • Mitin T, Zietman AL. Promise and pitfalls of heavy-particle therapy. J Clin Oncol 2014; 32:2855-63. PubMed
  • Chen RC, Hamstra DA, Sandler HM, Zietman AL. Complications of prostate cancer treatment. Lancet Oncol 2014; 15:e150. PubMed
  • Gray PJ, Lin CC, Jemal A, Shipley WU, Fedewa SA, Kibel AS, Rosenberg JE, Kamat AM, Virgo KS, Blute ML, Zietman AL, Efstathiou JA. Clinical-pathologic stage discrepancy in bladder cancer patients treated with radical cystectomy: results from the national cancer data base. Int J Radiat Oncol Biol Phys 2014; 88:1048-56. PubMed
  • Paly JJ, Hallemeier CL, Biggs PJ, Niemierko A, Roeder F, Martínez-Monge R, Whitson J, Calvo FA, Fastner G, Sedlmayer F, Wong WW, Ellis RJ, Haddock MG, Choo R, Shipley WU, Zietman AL, Efstathiou JA. Outcomes in a multi-institutional cohort of patients treated with intraoperative radiation therapy for advanced or recurrent renal cell carcinoma. Int J Radiat Oncol Biol Phys 2014; 88:618-23. PubMed
  • Wallner PE, Anscher MS, Barker CA, Bassetti M, Bristow RG, Cha YI, Dicker AP, Formenti SC, Graves EE, Hahn SM, Hei TK, Kimmelman AC, Kirsch DG, Kozak KR, Lawrence TS, Marples B, McBride WH, Mikkelsen RB, Park CC, Weidhaas JB, Zietman AL, Steinberg M. Current status and recommendations for the future of research, teaching, and testing in the biological sciences of radiation oncology: report of the American Society for Radiation Oncology Cancer Biology/Radiation Biology Task Force, executive summary. Int J Radiat Oncol Biol Phys 2014; 88:11-7. PubMed
  • Aizer AA, Paly JJ, Zietman AL, Nguyen PL, Beard CJ, Rao SK, Kaplan ID, Niemierko A, Hirsch MS, Wu CL, Olumi AF, Michaelson MD, D'Amico AV, Efstathiou JA. Models of care and NCCN guideline adherence in very-low-risk prostate cancer. J Natl Compr Canc Netw 2013; 11:1364-72. PubMed
  • Hoffman RM, Penson DF, Zietman AL, Barry MJ. Comparative effectiveness research in localized prostate cancer treatment. J Comp Eff Res 2013; 2:583-93. PubMed
  • Chen RC, Shipley WU, Efstathiou JA, Zietman AL. Trimodality bladder preservation therapy for muscle-invasive bladder cancer. J Natl Compr Canc Netw 2013; 11:952-60. PubMed
  • Carter HB, Albertsen PC, Barry MJ, Etzioni R, Freedland SJ, Greene KL, Holmberg L, Kantoff P, Konety BR, Murad MH, Penson DF, Zietman AL. Early detection of prostate cancer: AUA Guideline. J Urol 2013. PubMed
  • Mitin T, Hunt D, Shipley WU, Kaufman DS, Uzzo R, Wu CL, Buyyounouski MK, Sandler H, Zietman AL. Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre phase Lancet Oncol 2013; 14:863-72. PubMed
  • Hamstra DA, Conlon AS, Daignault S, Dunn RL, Sandler HM, Hembroff AL, Zietman AL, Kaplan I, Ciezki J, Kuban DA, Wei JT, Sanda MG, Michalski JM, . Multi-institutional prospective evaluation of bowel quality of life after prostate external beam radiation therapy identifies patient and treatment factors associated with patient-reported outcomes: the PROSTQA experience. Int J Radiat Oncol Biol Phys 2013. PubMed
  • Coen JJ, Paly JJ, Niemierko A, Kaufman DS, Heney NM, Spiegel DY, Efstathiou JA, Zietman AL, Shipley WU. Nomograms predicting response to therapy and outcomes after bladder-preserving trimodality therapy for muscle-invasive bladder cancer. Int J Radiat Oncol Biol Phys 2013. PubMed
  • Zietman AL. The Red Journal's most downloaded articles of 2012. Int J Radiat Oncol Biol Phys 2013; 86:218-21. PubMed
  • Gray PJ, Paly JJ, Yeap BY, Sanda MG, Sandler HM, Michalski JM, Talcott JA, Coen JJ, Hamstra DA, Shipley WU, Hahn SM, Zietman AL, Bekelman JE, Efstathiou JA. Patient-reported outcomes after 3-dimensional conformal, intensity-modulated, or proton beam radiotherapy for localized prostate cancer. Cancer 2013; 119:1729-35. PubMed
  • Efstathiou JA, Nassif DS, McNutt TR, Bogardus CB, Bosch W, Carlin J, Chen RC, Chou H, Eggert D, Fraass BA, Goldwein J, Hoffman KE, Hotz K, Hunt M, Kessler M, Lawton CA, Mayo C, Michalski JM, Mutic S, Potters L, Rose CM, Sandler HM, Sharp G, Tomé W, Tran PT, Wall T, Zietman AL, Gabriel PE, Bekelman JE. Practice-based evidence to evidence-based practice: building the National Radiation Oncology Registry. J Oncol Pract 2013; 9:e90-5. PubMed
  • Gray PJ, Fedewa SA, Shipley WU, Efstathiou JA, Lin CC, Zietman AL, Virgo KS. Use of potentially curative therapies for muscle-invasive bladder cancer in the United States: results from the National Cancer Data Base. Eur Urol 2013; 63:823-9. PubMed
  • Mitin T, Shipley WU, Efstathiou JA, Heney NM, Kaufman DS, Lee RJ, Zietman AL. Trimodality therapy for bladder conservation in treatment of invasive bladder cancer. Current Urology Reports 2013; 14:109-15. PubMed
  • Mouw KW, Trofimov A, Zietman AL, Efstathiou JA. Clinical controversies: proton therapy for prostate cancer. Semin Radiat Oncol 2013; 23:109-14. PubMed
  • Elnahal SM, Kerstiens J, Helsper RS, Zietman AL, Johnstone PA. Proton beam therapy and accountable care: the challenges ahead. Int J Radiat Oncol Biol Phys 2013; 85:e165-72. PubMed
  • Paly JJ, Efstathiou JA, Hedgire SS, Chung PW, O'Malley M, Shah A, Bekelman JE, Harisinghani M, Shipley WU, Zietman AL, Beard C. Mapping patterns of nodal metastases in seminoma: rethinking radiotherapy fields. Radiother Oncol 2013; 106:64-8. PubMed
  • Wallner PE, Ang KK, Zietman AL, Harris JR, Ibbott GS, Mahoney MC, Mezwa DG, Wilson LD, Becker GJ. The American Board of Radiology Holman Research Pathway: 10-year retrospective review of the program and participant performance. Int J Radiat Oncol Biol Phys 2013. PubMed
  • Aizer AA, Paly JJ, Zietman AL, Nguyen PL, Beard CJ, Rao SK, Kaplan ID, Niemierko A, Hirsch MS, Wu CL, Olumi AF, Michaelson MD, D'Amico AV, Efstathiou JA. Multidisciplinary care and pursuit of active surveillance in low-risk prostate cancer. J Clin Oncol 2012; 30:3071-6. PubMed
  • Kaufman DS, Zietman AL, Dahl DM, Harisinghani MG, Wu CL. Case records of the Massachusetts General Hospital. Case 5-2011. A 65-year-old man with hematuria after treatment for prostate cancer. N Engl J Med 2011; 364:667-75. PubMed
  • Zhang M, Coen JJ, Suzuki Y, Siedow MR, Niemierko A, Khor LY, Pollack A, Zhang Y, Zietman AL, Shipley WU, Chakravarti A. Survivin Is a Potential Mediator of Prostate Cancer Metastasis. Int J Radiat Oncol Biol Phys 2010; 78:1095-103. PubMed
  • Nguyen PL, Chen RC, Hoffman KE, Trofimov A, Efstathiou JA, Coen JJ, Shipley WU, Zietman AL, Talcott JA. Rectal Dose-Volume Histogram Parameters Are Associated with Long-Term Patient-Reported Gastrointestinal Quality of Life After Conventional and High-Dose Radiation for Prostate Cancer: A Subgroup Analysis of a Randomized Trial. Int J Radiat Oncol Biol Phys 2010; 78:1081-5. PubMed
  • Trofimov A, Nguyen PL, Efstathiou JA, Wang Y, Lu HM, Engelsman M, Merrick S, Cheng CW, Wong JR, Zietman AL. Interfractional Variations in the Setup of Pelvic Bony Anatomy and Soft Tissue, and Their Implications on the Delivery of Proton Therapy for Localized Prostate Cancer. Int J Radiat Oncol Biol Phys 2010. PubMed
  • Coen JJ, Bae K, Zietman AL, Patel B, Shipley WU, Slater JD, Rossi CJ. Acute and Late Toxicity After Dose Escalation to 82 GyE Using Conformal Proton Radiation for Localized Prostate Cancer: Initial Report of American College of Radiology Phase II Study 03-12. Int J Radiat Oncol Biol Phys 2010. PubMed
  • Coen JJ, Feldman AS, Smith MR, Zietman AL. Watchful waiting for localized prostate cancer in the PSA era: what have been the triggers for intervention? BJU Int 2010. PubMed
  • Katz MS, Efstathiou JA, D'Amico AV, Kattan MW, Sanda MG, Nguyen PL, Smith MR, Carroll PR, Zietman AL. The 'CaP Calculator': an online decision support tool for clinically localized prostate cancer. BJU Int 2010; 105:1417-22. PubMed
  • Talcott JA, Rossi C, Shipley WU, Clark JA, Slater JD, Niemierko A, Zietman AL. Patient-reported long-term outcomes after conventional and high-dose combined proton and photon radiation for early prostate cancer. JAMA 2010; 303:1046-53. PubMed
  • Zietman AL, Bae K, Slater JD, Shipley WU, Efstathiou JA, Coen JJ, Bush DA, Lunt M, Spiegel DY, Skowronski R, Jabola BR, Rossi CJ. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95-09. J Clin Oncol 2010; 28:1106-11. PubMed
  • Harrison LB, Zietman AL. American society for radiation oncology intersociety summit summary. Int J Radiat Oncol Biol Phys 2010; 76:643-8. PubMed
  • Efstathiou JA, Shipley WU, Zietman AL, Smith MR. Hormonal therapies: ADT for prostate cancer: true love or heartbreak? Nat Rev Clin Oncol 2010; 7:130-2. PubMed
  • Michalski JM,Lawton C,El Naqa I,Ritter M,O'Meara E,Seider MJ,Lee WR,Rosenthal SA,Pisansky T,Catton C,Valicenti RK,Zietman AL,Bosch WR,Sandler H,Buyyounouski MK,Menard C. Development of RTOG Consensus Guidelines for the Definition of the Clinical Target Volume for Postoperative Conformal Radiation Therapy for Prostate Cancer. Int J Radiat Oncol Biol Phys 2010; 76:361-8. PubMed
  • Lu-Yao GL, Albertsen PC, Moore DF, Shih W, Lin Y, DiPaola RS, Barry MJ, Zietman A, O'Leary M, Walker-Corkery E, Yao SL. Outcomes of localized prostate cancer following conservative management. JAMA 2009; 302:1202-9. PubMed
  • Wo JY,Shipley WU,Dahl DM,Coen JJ,Heney NM,Kaufman DS,Zietman AL. The results of concurrent chemo-radiotherapy for recurrence after treatment with bacillus Calmette-Guerin for non-muscle-invasive bladder cancer: is immediate cystectomy always necessary? BJU Int 2009; 104:179-83. PubMed
  • Coen JJ,Zietman AL. Proton radiation for localized prostate cancer. Nat Rev Urol 2009; 6:324-30. PubMed
  • Kaufman DS,Winter KA,Shipley WU,Heney NM,Wallace HJ 3rd,Toonkel LM,Zietman AL,Tanguay S,Sandler HM. Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy. Urology 2009; 73:833-7. PubMed
  • Mak RH,Zietman AL,Heney NM,Kaufman DS,Shipley WU. Bladder preservation: optimizing radiotherapy and integrated treatment strategies. BJU Int 2008; 102:1345-53. PubMed
  • Williams SG,Zietman AL. Does radical treatment have a role in the management of low-risk prostate cancer? The place for brachytherapy and external beam radiotherapy. World J Urol 2008; 26:447-56. PubMed
  • Wo JY,Zietman AL. Why does androgen deprivation enhance the results of radiation therapy? Urol Oncol 2008; 26:522-9. PubMed
  • Efstathiou JA, Skowronski RY, Coen JJ, Grocela JA, Hirsch AE, Zietman AL. Body Mass Index and Prostate-Specific Antigen Failure Following Brachytherapy for Localized Prostate Cancer. Int J Radiat Oncol Biol Phys 2008; 71:1302-8. PubMed
  • Michaelson MD,Cotter SE,Gargollo PC,Zietman AL,Dahl DM,Smith MR. Management of complications of prostate cancer treatment. CA Cancer J Clin 2008; 58:196-213. PubMed
  • Nguyen PL,Trofimov A,Zietman AL. Proton-beam vs intensity-modulated radiation therapy. Which is best for treating prostate cancer? Oncology (Huntingt) 2008; 22:748-54; discussion 754, 757. PubMed
  • Smith MR,Lee H,McGovern F,Fallon MA,Goode M,Zietman AL,Finkelstein JS. Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome. Cancer 2008; 112:2188-94. PubMed
  • Zietman A. Active surveillance: a safe, low-cost prognostic test for prostate cancer. BJU Int 2008; 101:1059-60. PubMed
  • Zietman AL. Correction: Inaccurate analysis and results in a study of radiation therapy in adenocarcinoma of the prostate. JAMA 2008; 299:898-9. PubMed
  • Hoffman KE, Hong TS, Zietman AL, Russell AH. External beam radiation treatment for rectal cancer is associated with a decrease in subsequent prostate cancer diagnosis. Cancer 2008; 112:943-9. PubMed
  • Trofimov A, Nguyen PL, Coen JJ, Doppke KP, Schneider RJ, Adams JA, Bortfeld TR, Zietman AL, Delaney TF, Shipley WU. Radiotherapy treatment of early-stage prostate cancer with IMRT and protons: a treatment planning comparison. Int J Radiat Oncol Biol Phys 2007; 69:444-53. PubMed
  • Nguyen PL, Zietman AL. High-dose external beam radiation for localized prostate cancer: current status and future challenges. Cancer J 2007; 13:295-301. PubMed
  • Zietman AL. The Titanic and the Iceberg: prostate proton therapy and health care economics. J Clin Oncol 2007; 25:3565-6. PubMed
  • Kaufman DS, McDougal WS, Zietman AL, Young RH. Case records of the Massachusetts General Hospital. Case 18-2007. A 54-year-old man with early-stage prostate cancer. N Engl J Med 2007; 356:2515-20. PubMed
  • Zelefsky MJ, Kuban DA, Levy LB, Potters L, Beyer DC, Blasko JC, Moran BJ, Ciezki JP, Zietman AL, Pisansky TM, Elshaikh M, Horwitz EM. Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation. Int J Radiat Oncol Biol Phys 2007; 67:327-33. PubMed
  • Frank SJ, Grimm PD, Sylvester JE, Merrick GS, Davis BJ, Zietman A, Moran BJ, Beyer DC, Roach M, Clarke DH, Stock RG, Robert Lee W, Michalski JM, Wallner KE, Hurwitz M, Potters L, Kuban DA, Prestidge BR, Vera R, Hathaway S, Blasko JC. Interstitial implant alone or in combination with external beam radiation therapy for intermediate-risk prostate cancer: a survey of practice patterns in the United States. Brachytherapy 2007; 6:2-8. PubMed
  • Ray ME, Levy LB, Horwitz EM, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Zelefsky MJ, Zietman AL, Kuban DA. Nadir prostate-specific antigen within 12 months after radiotherapy predicts biochemical and distant failure. Urology 2006; 68:1257-62. PubMed
  • Horwitz EM, Levy LB, Thames HD, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Sandler HM, Shipley WU, Zelefsky MJ, Zietman AL, Kuban DA. Biochemical and clinical significance of the posttreatment prostate-specific antigen bounce for prostate cancer patients treated with external beam radiation therapy alone: a multiinstitutional pooled analysis. Cancer 2006; 107:1496-502. PubMed
  • Kuban DA, Levy LB, Potters L, Beyer DC, Blasko JC, Moran BJ, Ciezki JP, Zietman AL, Zelefsky MJ, Pisansky TM, Elshaikh M, Horwitz EM. Comparison of biochemical failure definitions for permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2006; 65:1487-93. PubMed
  • Thames HD, Kuban DA, DeSilvio ML, Levy LB, Horwitz EM, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Sandler HM, Shipley WU, Zelefsky MJ, Zietman AL. Increasing external beam dose for T1-T2 prostate cancer: effect on risk groups. Int J Radiat Oncol Biol Phys 2006; 65:975-81. PubMed
  • Buscariollo DL, Drumm M, Niemierko A, Clayman RH, Galland-Girodet S, Rodin D, Feldman AS, M Dahl D, McGovern FJ, F Olumi A, Eidelman A, Shipley WU, Zietman AL, Efstathiou JA. Long-term results of adjuvant versus early salvage postprostatectomy radiation: A large single-institutional experience. ; 7:e125-e133. PubMed
  • Efstathiou JA, Trofimov AV, Zietman AL. Life, liberty, and the pursuit of protons: an evidence-based review of the role of particle therapy in the treatment of prostate cancer. Cancer J ; 15:312-8. PubMed
  • Zietman AL. The "Lee Decade": Bringing PRO From Conception to Maturity. ; 9:303-304. PubMed
  • Ross RW, Zietman AL, Xie W, Coen JJ, Dahl DM, Shipley WU, Kaufman DS, Islam T, Guimaraes AR, Weissleder R, Harisinghani M. Lymphotropic nanoparticle-enhanced magnetic resonance imaging (LNMRI) identifies occult lymph node metastases in prostate cancer patients prior to salvage radiation therapy. Clin Imaging ; 33:301-5. PubMed
Hide
Visualize Collaborations
Learn how these members are similar
Similar Members

DF/HCC members that share similar concepts* with Anthony L. Zietman, MD FASTRO but have yet to coauthor a publication with this researcher.

* Concepts are MeSH terms, automatically derived from member publications

Similar Members